Amgen’s cancer-drug pipeline looks promising despite FDA setback, analysts say
October 11, 2023 at 08:47 AM EDT
Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
|
||||||||||||
![]() |
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |